Research ArticleArticle
Bioengineered NRF2-siRNA Is Effective to Interfere with NRF2 Pathways and Improve Chemosensitivity of Human Cancer Cells
Peng-Cheng Li, Mei-Juan Tu, Pui Yan Ho, Joseph L. Jilek, Zhijian Duan, Qian-Yu Zhang, Ai-Xi Yu and Ai-Ming Yu
Drug Metabolism and Disposition January 2018, 46 (1) 2-10; DOI: https://doi.org/10.1124/dmd.117.078741
Peng-Cheng Li
Department of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China (P.-C.L., A.-X.Y.) and Department of Biochemistry and Molecular Medicine, Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, California (P.-C.L., M.-J.T., P.Y.H., J.L.J., Z.D., Q.-Y.Z., A.-M.Y.)
Mei-Juan Tu
Department of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China (P.-C.L., A.-X.Y.) and Department of Biochemistry and Molecular Medicine, Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, California (P.-C.L., M.-J.T., P.Y.H., J.L.J., Z.D., Q.-Y.Z., A.-M.Y.)
Pui Yan Ho
Department of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China (P.-C.L., A.-X.Y.) and Department of Biochemistry and Molecular Medicine, Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, California (P.-C.L., M.-J.T., P.Y.H., J.L.J., Z.D., Q.-Y.Z., A.-M.Y.)
Joseph L. Jilek
Department of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China (P.-C.L., A.-X.Y.) and Department of Biochemistry and Molecular Medicine, Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, California (P.-C.L., M.-J.T., P.Y.H., J.L.J., Z.D., Q.-Y.Z., A.-M.Y.)
Zhijian Duan
Department of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China (P.-C.L., A.-X.Y.) and Department of Biochemistry and Molecular Medicine, Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, California (P.-C.L., M.-J.T., P.Y.H., J.L.J., Z.D., Q.-Y.Z., A.-M.Y.)
Qian-Yu Zhang
Department of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China (P.-C.L., A.-X.Y.) and Department of Biochemistry and Molecular Medicine, Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, California (P.-C.L., M.-J.T., P.Y.H., J.L.J., Z.D., Q.-Y.Z., A.-M.Y.)
Ai-Xi Yu
Department of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China (P.-C.L., A.-X.Y.) and Department of Biochemistry and Molecular Medicine, Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, California (P.-C.L., M.-J.T., P.Y.H., J.L.J., Z.D., Q.-Y.Z., A.-M.Y.)
Ai-Ming Yu
Department of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China (P.-C.L., A.-X.Y.) and Department of Biochemistry and Molecular Medicine, Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, California (P.-C.L., M.-J.T., P.Y.H., J.L.J., Z.D., Q.-Y.Z., A.-M.Y.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
Bioengineered NRF2-siRNA Enhances Chemosensitivity
Peng-Cheng Li, Mei-Juan Tu, Pui Yan Ho, Joseph L. Jilek, Zhijian Duan, Qian-Yu Zhang, Ai-Xi Yu and Ai-Ming Yu
Drug Metabolism and Disposition January 1, 2018, 46 (1) 2-10; DOI: https://doi.org/10.1124/dmd.117.078741
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement